- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.02. | Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario | ||
| 10.02. | Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data | ||
| 10.02. | AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data | ||
| 10.02. | Evommune's Dupixent-like phase 2 eczema data drive 75% stock rally | ||
| 10.02. | AstraZeneca relaxed about relaxin drug's poor efficacy in phase 2 heart failure trial | ||
| 09.02. | FDA rejects Regenxbio's gene therapy in Hunter syndrome, leaving CEO 'concerned' | ||
| 09.02. | Lilly buys Orna in $2.4B deal to enter in vivo CAR-T arena | ||
| 09.02. | Roche unveils data behind BTK inhibitor's phase 3 multiple sclerosis win in Ocrevus trial | ||
| 09.02. | Lilly, Innovent pen $8.8B oncology, immunology collab that 'moves beyond traditional licensing' | ||
| 06.02. | UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge | ||
| 06.02. | Agomab, SpyGlass Pharma head to Nasdaq with IPOs totalling $350M | ||
| 05.02. | Racing BMS and J&J, Bayer links asundexian to 26% stroke reduction to unblock path to FDA | ||
| 05.02. | Angitia raises $130M to challenge Amgen with bone-building bispecifics | ||
| 05.02. | Flagship-founded antibody biotech Generate is latest to mull IPO | ||
| 05.02. | Quell halts liver transplant Treg trial to focus on preclinical 'chill not kill' candidate | ||
| 05.02. | Eikon's upsized $381M Nasdaq listing marks largest biotech IPO since 2024 | ||
| 04.02. | Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout | ||
| 04.02. | Novartis shakes up early pipeline with 6 culls and 2 new cancer candidates | ||
| 04.02. | Preclinical stem cell biotech PrimeGen takes SPAC route to Nasdaq | ||
| 04.02. | GSK's new CEO looking for $2B to $4B deals 'hiding in plain sight' | ||
| 04.02. | Novo's CEO 'wishes Pfizer luck' with Metsera drug, but still seeks own monthly GLP-1 | ||
| 03.02. | HHS launches $100M antiviral prize to develop broad-spectrum therapies | ||
| 03.02. | Fledgling biotech Exxel plans $13M IPO to succeed where other FAAH inhibitors have failed | ||
| 03.02. | Pfizer CEO says pipeline pruning is mostly finished after 6 more early-stage culls, $4.4B in impairment charges | ||
| 03.02. | Pfizer's $10B monthly GLP-1 bet generates competitive weight loss in phase 2b |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.